TSC-101

Cell therapy

On holdsponsor decision

Evidence outlook · program status

On hold (2026-09-02), as a strategic decision by the sponsor

TScan prioritised its preclinical solid-tumor programme and paused further enrolment in the Phase 3 ALLOHA-2 study of TSC-101. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

Company guidance: topline data expected mid-2028 (NCT07702578; TScan Therapeutics, Inc., 12 Aug 2026). “First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Hematologic Malignancies
Phase 1 (1)
Hematologic Malignancies
NCT05473910 · TScan Therapeutics, Inc.
2022-11-01 – 2028-06 · AML, MDS
What this study did

Competitive landscape

This drug's own stage for Hematologic Malignancies: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TSC-101: this drugPhase 3Cell therapyHA-2 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
TSC-100Phase 1Cell therapyHA-1 minor histocompatibility antigen (HLA-A*02:01)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Development is on hold since 2026-09-02 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.

2029 (1)
June 2029 (1)
Phase 3Hematologic MalignanciesActive not recruitingProgramme on hold
Est. primary completion 2029-06 · NCT07702578 · CT.gov ↗

Company guidance: topline data expected mid-2028 (TScan Therapeutics, Inc., 12 Aug 2026). “First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028” Source ↗

What to watch

See the full readout calendar ↗